Rituximab
Based on 16 publication(s) in Google Scholar
Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
For research use only. We do not sell to patients.
- Purity : 99.50%
- CAS No.: 174722-31-7
- Molecular Weight:143.47 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P9910
Obinutuzumab (FUT8-KO)Anti-CD20 Antibody -
HY-P9907
TrastuzumabHER2 Blocking Antibody -
HY-P9908
AdalimumabTNF-α Inhibitor -
HY-P9905
CetuximabEGFR Inhibitor -
HY-P9913A
Rituximab (anti-CD20)CD20 Inhibitor -
HY-P9970
InfliximabTNF-α Inhibitor -
HY-P9961
OfatumumabCD20 Inhibitor -
HY-15142
Doxorubicin hydrochlorideTopoisomerase Inhibitor -
HY-P9902
PembrolizumabPD-1 Inhibitor -
HY-P9906
BevacizumabVEGF-A Inhibitor -
HY-P99001
Human IgG1 kappa, Isotype ControlIgG1κ Isotype Control -
HY-17420
CyclophosphamideAlkylating Agent
Publications Citing Use of MedChemExpress (MCE) Rituximab
More- Signal Transduct Target Ther. 2020 Sep 14;5(1):200. [Abstract]
- Cancer Biol Med. 2020 Nov 15;17(4):1026-1038. [Abstract]
- EBioMedicine. 2024 Nov:109:105379. [Abstract]
- Clin Transl Med. 2025 May;15(5):e70336. [Abstract]
- Anal Chem. 2023 Apr 25;95(16):6700-6708. [Abstract]
- Anal Chim Acta. 2021 Apr 15:1154:338306. [Abstract]
- Cell Rep Methods. 2026 Jun 15;6(6):101416. [Abstract]
- Bioconjug Chem. 2025 Aug 21. [Abstract]
- Electrophoresis. 2026 Mar 24. [Abstract]
- Electrophoresis. 2025 Sep 23. [Abstract]
- Oncol Lett. 2026 Jun 17;32(2):357.
- J Immunol Methods. 2023 Nov:522:113552. [Abstract]
- University of Michigan. 2026.
- bioRxiv. 2026 May 27.
- bioRxiv. 2025 Oct 16.
- Research Square Preprint. 2022 Mar.
Customer Validation & Images
-
Flow Cytometry
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Flow Cytometry
-
Flow Cytometry
All Radionuclide-Drug Conjugates (RDCs) Isoforms
More
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
|
CD20/MS4A1 |
RDC Antibody |
In Vitro
Rituximab inhibits the proliferation of stimulated human B cells, which is associated with a relative increase of B cells with an activated naive phenotype. Aside from this population shift, there are no major changes in phenotype or cytokine profile of the various B-cell subsets. B cells stimulated in the presence of rituximab induces stronger T-cell proliferation, compared to B cells stimulated in the absence of rituximab[1]. All lymphoma cells tested are equally sensitive to antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated phagocytosis of tumor cells, and rituximab-induced apoptosis. Rituximab induces high CDC killing of follicular lymphoma cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD20/MS4A1 Protein-VLP, Human (HEK293, HY-P78543) can bind Rituximab. The ED50 for this effect is 6.149 ng/mL. -
Rituximab has a significant ADCC effect on Raji cells in a dose-dependent manner.The EC50 for this effect is 6.56 and 3.25 ng/mL.
Chemical Information
-
CAS No. 174722-31-7
-
Appearance Liquid
-
Molecular Weight 143.47 kDa
-
Color Colorless to light yellow
-
SMILES
[Rituximab]
-
Synonyms
Anti-Human CD20 type I, Chimeric Antibody; HSDB 7455; IDEC-C2B8
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (16)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma. [Abstract]2020 Sep 14;5(1):200. PMID: 32929063 -
Cancer Biol Med
Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers. [Abstract]2020 Nov 15;17(4):1026-1038. PMID: 33299651
Rituximab purchased from MedChemExpress. Usage Cited in: Cancer Biol Med. 2020 Nov 15;17(4):1026-1038. [Abstract]
Namalwa cells and Daudi cells were mixed with phosphate-buffered saline, rituximab (100 nM), or 161519 TriKE (100 nM) and incubated for 30 min at 37 °C.
-
EBioMedicine
Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial. [Abstract]2024 Nov:109:105379. PMID: 39368454
Rituximab purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2024 Nov:109:105379. [Abstract]
Biological activity of ADCC response induced by trastuzumab in BT474 and SKBR3 cells upon treatment with increasing concentrations of rituximab (6 h) was measured.
-
Clin Transl Med
IRF4 contributes to chemoresistance in IGH::BCL2-positive diffuse large B-cell lymphomas by mediating BCL2-induced SOX9 expression. [Abstract]2025 May;15(5):e70336. PMID: 40356256
Rituximab purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2025 May;15(5):e70336. [Abstract]
DLBCL cells were treated either with ABT-199, ABT-737, or R-CHOP (CHOP plus 10 µg/mL Rituximab) for 48 h.
-
Anal Chem
2023 Apr 25;95(16):6700-6708. PMID: 37052573 -
Anal Chim Acta
Calibration for quantitative Fc-glycosylation analysis of therapeutic IgG1-type monoclonal antibodies by using glycopeptide standards. [Abstract]2021 Apr 15:1154:338306. PMID: 33736796 -
Cell Rep Methods
Efficiency landscape of bioorthogonal click reactions producing bispecific antibody conjugates. [Abstract]2026 Jun 15;6(6):101416. PMID: 42019503 -
Bioconjug Chem
Resin-Supported Site-Specific Antibody Conjugation Method Leads to Antibody-Drug Conjugates with Retained Efficacy and Improved Stability. [Abstract]2025 Aug 21. PMID: 40839643 -
Electrophoresis
A Separation Buffers Platform Set to Facilitate CZE Charge Heterogeneity Method Development for Monoclonal Antibodies. [Abstract]2026 Mar 24. PMID: 41873887 -
Electrophoresis
Towards an Analytical Procedure Control Strategy for the Capillary Zone Electrophoresis Method for Monoclonal Antibodies: Alternatives for ε-Aminocaproic Acid and Triethylenetetramine. [Abstract]2025 Sep 23. PMID: 40988426
Rituximab purchased from MedChemExpress. Usage Cited in: Electrophoresis. 2025 Sep 23. [Abstract]
Overlay of CZE electropherograms of rituximab (1 mg/mL) and infliximab analysed using 400 mM eACA, 2 mM TETA, 0.05% HPMC, pH 5.7 (blue), 400 mM GABA, 2 mM TETA, 0.05% HPMC, pH 5.7 (red), 400 mM 7-AHA, 2 mM TETA, 0.05% HPMC, and pH 5.7 (green).
-
-
J Immunol Methods
Identifying therapeutic monoclonal antibodies using target protein collision electrophoresis reflex assay to separate the wheat from the chaff. [Abstract]2023 Nov:522:113552. PMID: 37652294 -
-
-
-
Rituximab purchased from MedChemExpress. Usage Cited in: Research Square Preprint. 2022 Mar.
In the case of rituximab (17 nM; 48 h) killing, flow cytometry detected the proportion of cells in the G2 phase of each group.
Purity & Documentation
-
Data Sheet (301 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50. [Content Brief]
[2]. Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54. [Content Brief]
[3]. Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Rituximab Related Classifications
HY-P9913 Related Classifications
Powered by Bioz